The Japan Times - Northway Biotech Launches Full-Service Viral Clearance Studies, Delivering Results Faster Than Industry Standards

EUR -
AED 4.033233
AFN 70.832917
ALL 90.300515
AMD 393.066954
ANG 1.966265
AOA 1008.170872
ARS 1704.735421
AUD 1.634069
AWG 1.976805
AZN 1.865603
BAM 1.953621
BBD 2.211224
BDT 137.127053
BGN 1.94767
BHD 0.414236
BIF 3301.402687
BMD 1.098225
BND 1.414915
BOB 12.806716
BRL 6.345768
BSD 1.09789
BTN 102.562671
BWP 15.367929
BYN 3.2948
BYR 21525.211443
BZD 2.208127
CAD 1.572054
CDF 2519.328333
CHF 0.923721
CLF 0.027742
CLP 1091.844327
CNY 7.320933
CNH 7.321405
COP 3634.048733
CRC 489.0523
CUC 1.098225
CUP 26.34961
CVE 110.143654
CZK 24.362976
DJF 195.511043
DKK 7.474333
DOP 66.485541
DZD 150.595324
EGP 58.9995
ERN 16.473376
ETB 180.196412
FJD 2.52361
FKP 0.830897
GBP 0.832487
GEL 2.84458
GGP 0.830897
GHS 12.88322
GIP 0.830897
GMD 81.268607
GNF 9727.1064
GTQ 8.390756
GYD 229.586609
HKD 8.616592
HNL 29.516943
HRK 7.503035
HTG 143.837603
HUF 367.015286
IDR 20059.080969
ILS 3.574822
IMP 0.830897
INR 102.562086
IQD 1664.428392
IRR 2118534.939608
ISK 136.806345
JEP 0.830897
JMD 174.464613
JOD 0.778629
JPY 174.916534
KES 142.824157
KGS 96.038643
KHR 4478.94315
KMF 492.004305
KPW 988.402951
KRW 1464.192117
KWD 0.342141
KYD 0.914971
KZT 487.441884
LAK 24727.419798
LBP 98319.17596
LKR 365.322531
LRD 184.442599
LSL 18.574267
LTL 3.242773
LVL 0.664305
LYD 7.095054
MAD 10.957778
MDL 20.103035
MGA 4994.383941
MKD 61.554724
MMK 2305.599623
MNT 3961.026963
MOP 8.873224
MRU 44.487178
MUR 52.648829
MVR 16.915638
MWK 1903.759271
MXN 20.263554
MYR 4.530728
MZN 70.172768
NAD 18.574014
NGN 1483.976329
NIO 40.40475
NOK 10.589751
NPR 164.101219
NZD 2.000629
OMR 0.422258
PAB 1.097875
PEN 3.749618
PGK 4.939423
PHP 69.951403
PKR 303.54618
PLN 4.404712
PYG 6840.339354
QAR 4.002291
RON 5.349123
RSD 117.633132
RUB 90.272028
RWF 1624.872871
SAR 4.130319
SBD 8.936303
SCR 15.209278
SDG 660.582753
SEK 11.140785
SGD 1.416299
SHP 0.831485
SLE 25.037179
SLL 23029.234705
SOS 627.397364
SRD 41.115348
STD 22731.041716
STN 24.47237
SVC 9.606198
SYP 14279.122777
SZL 18.57237
THB 37.218996
TJS 10.11707
TMT 3.843788
TND 3.32234
TOP 2.644263
TRY 55.395758
TTD 7.433641
TWD 36.182784
TZS 2910.294205
UAH 49.769735
UGX 4555.77344
USD 1.098225
UYU 44.600051
UZS 13194.283503
VES 1005.427142
VND 28204.067228
VUV 132.956262
WST 3.100598
XAF 655.957
XAG 0.023863
XAU 0.000290025121
XCD 2.968008
XCG 1.978675
XDR 0.776502
XOF 655.957
XPF 119.331742
YER 259.785175
ZAR 18.643691
ZMK 9885.337365
ZMW 22.490812
ZWL 353.628026
SSP 6511.055256
MXV 2.272663
  • RYCEF

    0.1000

    19.81

    +0.5%

  • VOD

    -0.2500

    16.33

    -1.53%

  • CMSC

    -0.2800

    20.12

    -1.39%

  • RBGPF

    -2.0000

    65

    -3.08%

  • RIO

    -0.2500

    94.16

    -0.27%

  • BTI

    -1.2000

    54.85

    -2.19%

  • NGG

    -0.3000

    74.94

    -0.4%

  • GSK

    -0.3500

    49.35

    -0.71%

  • BCE

    -0.4200

    20.14

    -2.09%

  • CMSD

    -0.3400

    19.93

    -1.71%

  • BP

    -0.9100

    43.52

    -2.09%

  • RELX

    0.1700

    33.24

    +0.51%

  • BCC

    -0.6200

    75.97

    -0.82%

  • AZN

    -1.9400

    164.21

    -1.18%

  • JRI

    0.0000

    10.77

    0%

Northway Biotech Launches Full-Service Viral Clearance Studies, Delivering Results Faster Than Industry Standards
Northway Biotech Launches Full-Service Viral Clearance Studies, Delivering Results Faster Than Industry Standards

Northway Biotech Launches Full-Service Viral Clearance Studies, Delivering Results Faster Than Industry Standards

With six newly established, identical BSL-2 laboratories now operational, biologics CDMO Northway Biotech can conduct VCS programs for up to six clients simultaneously, significantly alleviating current market bottlenecks

Text size:

VILNIUS, LT / ACCESS Newswire / May 5, 2025 / Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), today announced the expansion of its protein-based and gene therapy service offerings with the addition of Viral Clearance Studies (VCS) capabilities. This strategic growth follows the opening of Northway Biotech's new Gene Therapy Center with dedicated cGMP facilities for virus-related projects.

With six newly established, identical BSL-2 laboratories now operational, Northway Biotech can conduct VCS programs for up to six clients simultaneously, significantly alleviating current market bottlenecks. Additionally, the company has expanded its capabilities to perform GMP-compliant manufacturing and testing under BSL-3 conditions, further strengthening its service offering across gene therapy and broader biologics development.

Viral Clearance Studies are now offered both as part of Northway Biotech's integrated CDMO programs and as a standalone service. This flexibility allows external clients to access VCS expertise independently, without requiring a manufacturing agreement.

Accelerated Delivery Timelines - Over One Month Faster Than Industry

Leveraging expanded infrastructure and integrated analytical capabilities, Northway Biotech is positioned to deliver Viral Clearance Studies substantially faster than the current industry standard. Comprehensive studies, assessing viral removal and inactivation, can now be completed with final regulatory-compliant reporting in under 10 weeks from initiation of project design when two model viruses are employed, and within 12 weeks when four model viruses are used.

"Our expansion into Viral Clearance Studies is a natural extension of our CDMO services, enabling us to manage these critical studies in-house and significantly reduce project timelines for our clients," said Prof. Vladas Algirdas Bumelis, CEO of Northway Biotech. "By investing in state-of-the-art BSL-2 and BSL-3 facilities, expanding technical capabilities, and further strengthening our scientific teams, we are uniquely positioned to deliver high-quality VCS data faster - a key advantage for clients advancing through clinical development and regulatory approval."

For more information on Northway Biotech's Viral Clearance Study processes, service offerings, and delivery timelines, please complete the contact form to connect with the Northway Biotech team.

About Northway Biotech - https://www.northwaybiotech.com

Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced and professional team executes projects at every stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's extensive expertise and vertically integrated service offering enables rapid execution of multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development, and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and operates locations in Vilnius, Lithuania; London, United Kingdom; and Waltham, MA, USA.

Media & Business Contact:

[email protected]

Prof. Vladas Algirdas Bumelis
CEO and Chairman of the Board
Northway Biotech
[email protected]

Contact Information

Vladas Bumelis
CEO and Chairman of the Board
[email protected]

SOURCE: Northway Biotech



View the original press release on ACCESS Newswire

Y.Hara--JT